It’s time we seriously consider adding to the Virtue team. If you obsess over early stage healthcare, value an active engaged investment strategy (8-12 new cos/yr), are ambitious & willing to put in the work and can help sharpen our edge - or know someone who is wired this

Fantastic overview on our port co, Tuva Health! H/T Nikhil Krishnan TLDR — healthcare data is messy, nuanced and often regulated in ways that make it hard to use. Tuva transforms raw healthcare data into analytics-ready data that data & biz teams can use 🔧 bit.ly/3QeVkFG

Let's go Tuva!!!

Integral is hiring a design lead! Integral is creating the healthcare compliance OS and is one of our most exciting (and fastest growing) partnerships! Check out more on Integral here - useintegral.com.

Great write up on our port co, Tuva Health, from the Pear VC team on how Tuva is democratizing healthcare data analytics! pearhealthcareplaybook.substack.com/p/lessons-from…

What a year Virtue! - 7 new investments; led/co-led 6/7; ownership 39% ⬆️ YoY; entry val 15% ⬇️ YoY - 7 markups. 5 Series A, 2 Seed; 100% grad rate; ~35% above A/Seed mkt median valuation - 17 total cos - A stronger, long-term LP base Here's to a better & brighter '24 🚀

*Care delivery counter narrative* In H2-23 we Virtue were fortunate to have 7 portfolio co markups. Interestingly, 5/7 were care delivery models even though care delivery only represents <40% of our cost basis, which is much lower than most healthcare VC portfolios (even

Sean Doolan Virtue 100%. Some common themes we see in the early days for these co's include: 1. Scalable patient acquisition 2. High $ / defined episode 3. Clear attribution of value 4. Operational scale over time to drive care margins (tech, group models, non-clinical staff, flexibility in VBC)

🎯 there’s a growing roster of generational AI-first healthcare cos being built rn. 🔓 the biggest unlock to our GDP over the next decade will be from driving massive productivity gains in the healthcare sector.

📢📢 Today on the venturevoices podcast we have Sean Doolan from Virtue! Tune in to learn how Sean is building Virtue as the go-to pre-seed and seed stage healthcare-focused firm Audio: open.spotify.com/episode/0uWlVO… Video: youtu.be/Q0jcd8ob-o4?si…

Thank you Richard Kerby for having me! That was a lot of fun… plus it was time to finally rip the bandaid off & share the Virtue story. More to come but TLDR we exclusively partner with pre-seed & seed healthcare founders intent on radically transforming our healthcare ecosystem.

Excited to highlight the $15M Series A in our Virtue portfolio co Amae Health! Amae has developed an integrative care model serving the >14M US adults suffering from untreated Serious Mental Illness (SMI). Way to go Stas & Sonia! bit.ly/44iRlPa

We talk about the future potential of AI to transform healthcare, but SmarterDx has proven that future is already here. 5:1 ROI, 100% customer retention and a 98 KLAS Research score = happy customers. Congrats to Mike Gao, Josh Geleris and team! Thrilled for what's ahead 🚀

Truly a standout RCM business — SmarterDx is changing the mid-RCM landscape and setting a new standard for hospitals and health systems. Congrats on your $50M Series B guys! Check out more here smarterdx.com

🚨 Virtue is hiring! We are seeking a Partner / Principal to join our growing firm as we expand into our Fund II. You will play a lead role across key strategic areas - investment process, portfolio mgmt, and investor relations. APPLY HERE ➡️ bit.ly/3z0wYKE

Thanks for the shutout ⁦Kosta Buhler⁩! We ⁦Virtue⁩ deeply value working with you and the ⁦Sequoia Capital⁩ team! 👊🏼 cc ⁦@jason⁩ ⁦This Week in Startups⁩ podcasts.apple.com/us/podcast/thi…

After 2.5 years we are excited to finally talk about Seen Health! One of our Virtue earliest investments! Seen Health is building a tech-enabled, culturally-focused PACE program to serve high-needs seniors in Asian communities who have historically been underserved due to

At Virtue we are massively bullish on open source and tooling that can access untapped and/or underutilized data assets so that data and business users can extract meaningful insights that ultimately improve clinical, financial and operational performance. And, AI demands

We are finally able to share more about our investment in Prudentia Sciences! Prudentia offers a AI-driven approach for early-stage drug asset evaluation, delivering precise NPV estimates that help pharma and investors (hedge funds, VCs, and PEs) optimally allocate resources.

Announcing our $55.75M "V2" Fund II -- primed and ready to deploy!